PRELIMINARY FINDINGS FROM THE PHASE 2 EPPIK STUDY OF SPARSENTAN IN PEDIATRIC PATIENTS WITH SELECTED PROTEINURIC GLOMERULAR DISEASES
Back
E-Poster
https://storage.unitedwebnetwork.com/files/1099/aa8bdbeaeed88b5ebf160c2881f5ce7d.pdf
Abstract Title
PRELIMINARY FINDINGS FROM THE PHASE 2 EPPIK STUDY OF SPARSENTAN IN PEDIATRIC PATIENTS WITH SELECTED PROTEINURIC GLOMERULAR DISEASES
First Name *
Radko
Last Name *
Komers
Co-author 1
Rosanna Coppo rosanna.coppo@unito.it Fondazione Ricerca Molinette, Regina Margherita Hospital N/A Turin
Co-author 2
Nuhira Ahmed Masthan Ahmed nuhira.masthan@travere.com Travere Therapeutics, Inc. Biostatistics San Diego
Co-author 3
Kenneth V. Lieberman kenneth.lieberman@hmhn.org Joseph M Sanzari Children's Hospital of the Hackensack Meridian Health Network Department of Pediatrics Division of Pediatric Nephrology Hackensack
Co-author 4
Alex Mercer alex.mercer@travere.com JAMCO Pharma Consulting N/A Stockholm
Co-author 5
Michelle Rheault rheau002@umn.edu University of Minnesota Medical School Division of Pediatric Nephrology Minneapolis
Co-author 6
Moin A. Saleem m.saleem@bristol.ac.uk University of Bristol & Bristol Royal Hospital for Children Bristol Renal Bristol
Co-author 7
Teresa Shafer teresa.shafer@travere.com Travere Therapeutics, Inc. Clinical Operations San Diego
Co-author 8
Howard Trachtman howardtrachtman21@gmail.com University of Michigan Department of Pediatrics, Division of Nephrology Ann Arbor
Co-author 9
Co-author 10
Co-author 11
Co-author 12
Co-author 13
Co-author 14
Co-author 15
E-Poster Format Requirements
PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but
must be saved and submitted as PDF file
.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos